Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Name: Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
Published: 2019
License: Public Domain

Bristol-Myers Squibb · 2019

ClinicalTrials.gov · Datasets · License: Public Domain · 2019

Open Source ↗

breast-cancer cancer nivolumab

breast cancer, nivolumab, cancer, estrogen receptor-positive (er+), human epidermal growth factor 2 negative (her2-), neoadjuvant, adjuvant, primary breast cancer, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Related documents